REDWOOD
CITY, Calif., Nov. 1, 2023
/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device
company that is delivering comprehensive, life-changing solutions
for the treatment of chronic pain, today reported its third quarter
2023 financial results. The Company also provided fourth quarter
guidance and updated its full-year 2023 guidance.
Recent Business Highlights and Guidance
- Third Quarter 2023 Worldwide Revenue of $103.9 Million Grew 3% As Reported and Constant
Currency Compared to Third Quarter 2022
- Painful Diabetic Neuropathy (PDN) Indication Sales of
Approximately $20.8 Million Grew 56%
Compared to Third Quarter 2022
- Third Quarter 2023 U.S. Trial Procedures Increased 4% Compared
to Third Quarter 2022, while U.S. PDN Trial Procedures Represented
24% of Total U.S. Trials in the Quarter
- Third Quarter 2023 Net Loss from Operations of $25.6 Million; Third Quarter 2023 Non-GAAP
Adjusted EBITDA Loss of $5.8
Million
- Strong 24-month data (90.1% Responder Rate) from the SENZA PDN
Randomized Controlled Trial, which demonstrated long-term efficacy
of high-frequency 10 kHz SCS to treat refractory PDN, published in
Diabetes Research and Clinical Practice
- Provides Fourth Quarter 2023 Revenue Guidance of $108 Million to $110
Million; Updates Full-Year 2023 Revenue Guidance to
$417 Million to $419 Million, or 3% Constant Currency Growth Over
2022
- Provides Fourth Quarter 2023 Non-GAAP Adjusted EBITDA Guidance
of Positive $1 Million to Positive
$2 Million; Updates Full-Year 2023
Non-GAAP Adjusted EBITDA Guidance to Negative $24 Million to Negative $25 Million
Third Quarter 2023 Financial Overview
Worldwide revenue for the third quarter of 2023 was $103.9 million, an increase of 3% as reported and
on a constant currency basis, compared to $100.5 million in the third quarter of 2022. PDN
indication sales represented approximately $20.8 million and 20% of worldwide permanent
implant procedures in the third quarter of 2023.
U.S. revenue in the third quarter of 2023 was $89.8 million, reflecting growth of 4% over
$86.1 million in the third quarter of
2022. U.S. permanent implant procedures increased 7% compared to
the third quarter of 2022, while U.S. trial procedures increased 4%
compared to the third quarter of 2022. U.S. PDN trial procedures
represented approximately 24% of total U.S. trial volume and grew
approximately 41% over the third quarter of 2022.
International revenue in the third quarter of 2023 was
$14.1 million, compared to
$14.3 million in the third quarter of
2022, a decrease of 2% as reported or a decrease of 6% on a
constant currency basis.
"I am very pleased with our third quarter results. The changes
and processes we put in place over the past five months are well
underway, and we are beginning to experience the positive results
from them," said Kevin Thornal,
Nevro's CEO and President. "While we are encouraged by the early
momentum we are experiencing, we know it will take several quarters
for our financial results to fully reflect the positive changes we
have made throughout the Company. We are excited about the
opportunities ahead and delivering on our three core pillars:
commercial execution, market penetration, and profit progress."
Gross profit for the third quarter of 2023 was $69.5 million, compared to $69.3 million in the third quarter of 2022. Gross
margin was 66.9% in the third quarter of 2023, compared to 69.0% in
the third quarter of 2022. "The full market release of the HFX iQ
system continues to progress well. We are capturing a pricing
uplift on our HFX iQ product, which is currently being offset by
legacy product pricing pressures. We remain optimistic on our long
run margin expansion opportunities with our Costa Rica sourced products," added
Rod MacLeod, Chief Financial Officer.
Operating expenses for the third quarter of 2023 were
$95.1 million, compared to
$92.2 million in the third quarter of
2022, excluding $105.0 million of
certain litigation credits in the third quarter of 2022. The
increase in operating expenses was primarily due to litigation and
personnel related costs, partially offset by a decrease in
stock-based compensation. Litigation-related legal expenses were
$4.3 million for the third quarter of
2023, compared to $1.9 million in the
third quarter of 2022.
Net loss from operations for the third quarter of 2023 was
$25.6 million, compared to net income
of $82.1 million, or a loss of
$22.9 million in the third quarter of
2022, excluding the $105.0 million of
litigation-related credits. Non-GAAP adjusted EBITDA for the third
quarter of 2023 was a loss of $5.8
million, compared to a loss of $3.8
million in the third quarter of 2022. Non-GAAP adjusted
EBITDA excludes interest, taxes, and non-cash items such as
stock-based compensation, depreciation and amortization,
restructuring charges, litigation-related expenses, and certain
litigation charges and credits. Please see the financial table
below for GAAP to non-GAAP reconciliations.
Cash, cash equivalents, and short-term investments totaled
$320.3 million as of September 30, 2023, a decrease of $9.7 million from June 30,
2023. This decrease was primarily driven by cash used in
operations.
Fourth Quarter and Full-Year 2023 Guidance
Nevro expects fourth quarter of 2023 worldwide revenue of
approximately $108 million to
$110 million, or a decrease of 4% to
6% over prior year on a constant currency basis.
The Company expects fourth quarter of 2023 non-GAAP adjusted
EBITDA to be a gain of approximately $1
million to $2 million.
Non-GAAP adjusted EBITDA excludes interest, taxes, and non-cash
items such as stock-based compensation and depreciation and
amortization, as well as litigation-related expenses, certain
litigation charges and credits and other adjustments such as
restructuring charges. Please see the financial tables for GAAP to
non-GAAP reconciliations.
The Company now expects full-year 2023 worldwide revenue of
approximately $417 million to
$419 million, an increase of 3% over
prior year on both an as reported and constant currency basis. This
compares to previous guidance of $410 million to
$415 million.
The Company now expects full-year 2023 non-GAAP adjusted EBITDA
to be a loss of approximately $24
million to $25 million, compared to previous guidance
of a loss of $25 million to $28 million and a non-GAAP
adjusted EBITDA loss of $23.8 million
in 2022. Please see the financial tables for GAAP to non-GAAP
reconciliations.
An investor presentation for the Company's third quarter 2023
financial results is available in the "Investors" section of
Nevro's website at www.nevro.com.
Webcast and Conference Call Information
As previously announced, Nevro management will host a conference
call starting at 1:30 pm PT /
4:30 pm ET today. Investors
interested in listening to the call may do so by dialing (888)
330-2443 in the U.S. or +1 (240) 789-2728 internationally, using
Conference ID: 3583097. A live webcast, as well as an archived
recording, will also be available in the "Investors" section of
Nevro's website at: www.nevro.com.
Internet Posting of Information
Nevro routinely posts information that may be important to
investors in the "Investor Relations" section of its website at
www.nevro.com. The Company encourages investors and potential
investors to consult the Nevro website regularly for important
information about Nevro.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on delivering comprehensive, life-changing solutions that continue
to set the standard for enduring patient outcomes in chronic pain
treatment. The Company started with a simple mission to help more
patients suffering from debilitating pain and developed its
proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic
innovation that has impacted the lives of more than 100,000
patients globally. Nevro's comprehensive HFX™ spinal cord
stimulation (SCS) platform includes a Senza SCS system and support
services for the treatment of chronic pain of the trunk and limb
and painful diabetic neuropathy.
Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS
systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's
unique support services provide every patient with an HFX Coach™
throughout their pain relief journey and every physician with HFX
Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo,
RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are
trademarks or registered trademarks of Nevro Corp. Patents covering
Senza HFX iQ and other Nevro products are listed at
Nevro.com/patents.
To learn more about Nevro, connect with us
on LinkedIn, Twitter, Facebook and Instagram.
Forward-Looking Statements
In addition to historical information, this press release
contains forward-looking statements reflecting the Company's
current beliefs and expectations of management made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995, including: our fourth quarter and updated full-year
2023 financial guidance; our belief that it will take several
quarters for our financial results to fully reflect the positive
changes we have made throughout the Company; our belief that our
three key pillars for our strategic focus will improve our
commercial execution and deliver significant long-term shareholder
return; and our belief in long run margin expansion opportunities
with our Costa Rica sourced
products. These forward-looking statements are based upon
information that is currently available to us or our current
expectations, speak only as of the date hereof, and are subject to
numerous risks and uncertainties, including our ability to
successfully commercialize our products; our ability to manufacture
our products to meet demand; the level and availability of
third-party payor reimbursement for our products; our ability to
effectively manage our anticipated growth and the costs and
expenses of operating our business; our ability to protect our
intellectual property rights and proprietary technologies; our
ability to operate our business without infringing the intellectual
property rights and proprietary technology of third parties;
competition in our industry; additional capital and credit
availability; our ability to successfully integrate any additive
acquisitions we may make; our ability to attract and retain
qualified personnel; our ability to accurately forecast financial
and operating results; and product liability claims. These factors,
together with those that are described in greater detail in our
Annual Report on Form 10-K filed on February
21, 2023, as well as any reports that we may file with the
Securities and Exchange Commission in the future, may cause our
actual results, performance or achievements to differ materially
and adversely from those anticipated or implied by our
forward-looking statements. We expressly disclaim any obligation,
except as required by law, or undertaking to update or revise any
such forward-looking statements. Nevro's operating results for the
third quarter ended September 30,
2023 are not necessarily indicative of our operating results
for any future periods.
Nevro
Corp.
|
Condensed
Consolidated Statements of Operations and Comprehensive
Loss
|
(in thousands,
except share and per share data)
|
|
|
|
Three Months
Ended
|
|
|
Nine Months
Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
|
2023
|
|
|
2022
|
|
|
|
(unaudited)
|
|
|
(unaudited)
|
|
Revenue
|
|
$
|
103,862
|
|
|
$
|
100,466
|
|
|
$
|
308,998
|
|
|
$
|
292,521
|
|
Cost of
revenue
|
|
|
34,346
|
|
|
|
31,164
|
|
|
|
100,415
|
|
|
|
91,393
|
|
Gross profit
|
|
|
69,516
|
|
|
|
69,302
|
|
|
|
208,583
|
|
|
|
201,128
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
|
13,923
|
|
|
|
14,030
|
|
|
|
41,998
|
|
|
|
39,118
|
|
Sales, general and
administrative
|
|
|
81,152
|
|
|
|
78,190
|
|
|
|
254,106
|
|
|
|
241,488
|
|
Certain litigation
charges (credits)
|
|
|
—
|
|
|
|
(105,000)
|
|
|
|
—
|
|
|
|
(105,000)
|
|
Total operating
expenses
|
|
|
95,075
|
|
|
|
(12,780)
|
|
|
|
296,104
|
|
|
|
175,606
|
|
Income (loss) from
operations
|
|
|
(25,559)
|
|
|
|
82,082
|
|
|
|
(87,521)
|
|
|
|
25,522
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
(expense), net
|
|
|
1,976
|
|
|
|
(480)
|
|
|
|
5,371
|
|
|
|
(3,266)
|
|
Other income
(expense), net
|
|
|
234
|
|
|
|
391
|
|
|
|
(150)
|
|
|
|
844
|
|
Income (loss) before
income taxes
|
|
|
(23,349)
|
|
|
|
81,993
|
|
|
|
(82,300)
|
|
|
|
23,100
|
|
Provision for income
taxes
|
|
|
130
|
|
|
|
485
|
|
|
|
932
|
|
|
|
907
|
|
Net income
(loss)
|
|
|
(23,479)
|
|
|
|
81,508
|
|
|
|
(83,232)
|
|
|
|
22,193
|
|
Changes in foreign
currency translation adjustment
|
|
|
(765)
|
|
|
|
(1,690)
|
|
|
|
77
|
|
|
|
(3,293)
|
|
Changes in unrealized
gains (losses) on short-term
investments
|
|
|
470
|
|
|
|
(102)
|
|
|
|
865
|
|
|
|
(1,384)
|
|
Net change in other
comprehensive income (loss)
|
|
|
(295)
|
|
|
|
(1,792)
|
|
|
|
942
|
|
|
|
(4,677)
|
|
Comprehensive income
(loss)
|
|
$
|
(23,774)
|
|
|
$
|
79,716
|
|
|
$
|
(82,290)
|
|
|
$
|
17,516
|
|
Net income (loss) per
common share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.65)
|
|
|
$
|
2.30
|
|
|
$
|
(2.32)
|
|
|
$
|
0.63
|
|
Diluted
|
|
$
|
(0.65)
|
|
|
$
|
2.22
|
|
|
$
|
(2.32)
|
|
|
$
|
0.63
|
|
Weighted average shares
used to compute
net income
(loss) per share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
36,142,255
|
|
|
|
35,402,086
|
|
|
|
35,882,826
|
|
|
|
35,265,193
|
|
Diluted
|
|
|
36,142,255
|
|
|
|
37,338,945
|
|
|
|
35,882,826
|
|
|
|
35,501,609
|
|
Nevro
Corp.
|
Condensed
Consolidated Balance Sheets
|
(in thousands,
except share and per share data)
|
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2023
|
|
|
2022
|
|
|
|
(unaudited)
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
65,155
|
|
|
$
|
120,373
|
|
Short-term
investments
|
|
|
255,103
|
|
|
|
254,012
|
|
Accounts receivable,
net
|
|
|
68,984
|
|
|
|
78,930
|
|
Inventories,
net
|
|
|
122,420
|
|
|
|
99,638
|
|
Prepaid expenses and
other current assets
|
|
|
10,321
|
|
|
|
9,984
|
|
Total current
assets
|
|
|
521,983
|
|
|
|
562,937
|
|
Property and equipment,
net
|
|
|
24,031
|
|
|
|
22,271
|
|
Operating lease
assets
|
|
|
10,099
|
|
|
|
13,430
|
|
Other assets
|
|
|
4,863
|
|
|
|
3,164
|
|
Restricted
cash
|
|
|
606
|
|
|
|
606
|
|
Total
assets
|
|
$
|
561,582
|
|
|
$
|
602,408
|
|
Liabilities and
stockholders' equity
|
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
28,854
|
|
|
$
|
26,849
|
|
Accrued liabilities
and other
|
|
|
50,889
|
|
|
|
52,363
|
|
Total current
liabilities
|
|
|
79,743
|
|
|
|
79,212
|
|
Long-term
debt
|
|
|
187,803
|
|
|
|
186,867
|
|
Long-term operating
lease liabilities
|
|
|
6,105
|
|
|
|
10,296
|
|
Other long-term
liabilities
|
|
|
2,265
|
|
|
|
2,157
|
|
Total
liabilities
|
|
|
275,916
|
|
|
|
278,532
|
|
Stockholders'
equity
|
|
|
|
|
|
|
|
|
Common stock, $0.001
par value, 290,000,000 shares authorized;
36,869,962 and
36,203,423 shares issued at September 30, 2023
and December
31, 2022, respectively; 36,187,046 and 35,520,507
shares
outstanding at September 30, 2023 and December 31,
2022,
respectively
|
|
|
36
|
|
|
|
35
|
|
Additional paid-in
capital
|
|
|
978,211
|
|
|
|
934,132
|
|
Accumulated other
comprehensive loss
|
|
|
(2,152)
|
|
|
|
(3,094)
|
|
Accumulated
deficit
|
|
|
(690,429)
|
|
|
|
(607,197)
|
|
Total stockholders'
equity
|
|
|
285,666
|
|
|
|
323,876
|
|
Total liabilities and
stockholders' equity
|
|
$
|
561,582
|
|
|
$
|
602,408
|
|
Nevro Corp.
GAAP to Non-GAAP
Adjusted EBITDA Reconciliation
(unaudited)
(in
thousands)
The following table presents a reconciliation of GAAP net loss,
as prepared in accordance with U.S. Generally Accepted Accounting
Principles ("GAAP"), to Adjusted EBITDA, a non-GAAP financial
measure.
Reconciliation of
actual results:
|
|
|
|
Three Months
Ended
|
|
|
Nine Months
Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
|
2023
|
|
|
2022
|
|
|
|
(unaudited)
|
|
|
(unaudited)
|
|
GAAP Net Income
(Loss)
|
|
$
|
(23,479)
|
|
|
$
|
81,508
|
|
|
$
|
(83,232)
|
|
|
$
|
22,193
|
|
Non-GAAP
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest (income)
expense, net
|
|
|
(1,976)
|
|
|
|
480
|
|
|
|
(5,371)
|
|
|
|
3,266
|
|
Provision for income
taxes
|
|
|
130
|
|
|
|
485
|
|
|
|
932
|
|
|
|
907
|
|
Depreciation and
amortization
|
|
|
1,723
|
|
|
|
1,642
|
|
|
|
5,016
|
|
|
|
4,780
|
|
Stock-based
compensation expense
|
|
|
13,523
|
|
|
|
15,206
|
|
|
|
43,249
|
|
|
|
41,992
|
|
Certain litigation
charges (credits)
|
|
|
—
|
|
|
|
(105,000)
|
|
|
|
—
|
|
|
|
(105,000)
|
|
Litigation-related
expenses
|
|
|
4,284
|
|
|
|
1,884
|
|
|
|
12,972
|
|
|
|
9,513
|
|
Restructuring
charges
|
|
|
—
|
|
|
|
—
|
|
|
|
373
|
|
|
|
—
|
|
Adjusted
EBITDA
|
|
$
|
(5,795)
|
|
|
$
|
(3,795)
|
|
|
$
|
(26,061)
|
|
|
$
|
(22,349)
|
|
Reconciliation of
guidance:
|
|
|
|
Three Months
Ended
|
|
|
Year
Ended
|
|
|
|
December 31,
2023
|
|
|
December 31,
2023
|
|
|
|
(Low
Case)
|
|
|
(High
Case)
|
|
|
(Low
Case)
|
|
|
(High
Case)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Net
Loss
|
|
$
|
(15,800)
|
|
|
$
|
(14,800)
|
|
|
$
|
(99,000)
|
|
|
$
|
(98,000)
|
|
Non-GAAP
Adjustments
|
|
|
16,800
|
|
|
|
16,800
|
|
|
|
74,000
|
|
|
|
74,000
|
|
Adjusted
EBITDA
|
|
$
|
1,000
|
|
|
$
|
2,000
|
|
|
$
|
(25,000)
|
|
|
$
|
(24,000)
|
|
Management uses certain non-GAAP financial measures, most
specifically Adjusted EBITDA, as a supplement to GAAP financial
measures to further evaluate the Company's operating performance
period over period, analyze the underlying business trends, assess
performance relative to competitors and establish operational
objectives.
Management believes it is important to provide investors with
the same non-GAAP metrics it uses to evaluate the performance and
underlying trends of the Company's business operations to
facilitate comparisons to its historical operating results and
evaluate the effectiveness of its operating strategies. Disclosure
of these non-GAAP financial measures also facilitates comparisons
of the Company's underlying operating performance with other
companies in the industry that also supplement their GAAP results
with non-GAAP financial measures.
EBITDA is a non-GAAP financial measure, which is calculated by
adding interest income and expense, net; provision for income
taxes; and depreciation and amortization to net income. In
calculating non-GAAP Adjusted EBITDA, the Company further adjusts
for the following items:
- Stock-based compensation expense – The Company excludes
non-cash costs related to the Company's stock-based plans, which
include stock options, restricted stock units and performance-based
restricted stock units as these expenses do not require cash
settlement from the Company.
- Certain litigation charges (credits) – The Company excludes
certain non-recurring litigation charges (credits) associated with
patent litigation legal judgement and settlement, which management
considers not related to the underlying operating performance of
the business.
- Litigation-related expenses – The Company excludes legal and
professional fees as well as charges and credits associated with
certain legal matters, which management considers not related to
the underlying operating performance of the business.
- Restructuring charges – The Company excludes charges incurred
as a direct result of restructuring programs, such as salaries and
other compensation-related expenses.
Full-year guidance excludes the impact of foreign currency
fluctuations.
The non-GAAP financial measure should not be considered in
isolation from, or as a replacement for, the most directly
comparable GAAP financial measures, as it is not prepared in
accordance with U.S. GAAP.
Amounts may not add due to rounding.
The following table presents the reconciliation of net income
(loss) used in computing basic and diluted net income (loss) per
common share (in thousands):
|
|
Three Months
Ended
|
|
|
Nine Months
Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
|
2023
|
|
|
2022
|
|
Net income (loss) used
in basic net income (loss) per
common
share
|
|
$
|
(23,479)
|
|
|
$
|
81,508
|
|
|
$
|
(83,232)
|
|
|
$
|
22,193
|
|
Plus:
Assumed conversions of
dilutive convertible notes
|
|
|
—
|
|
|
|
1,305
|
|
|
|
—
|
|
|
|
—
|
|
Net income (loss) used
in diluted net income (loss) per
common
share
|
|
$
|
(23,479)
|
|
|
$
|
82,813
|
|
|
$
|
(83,232)
|
|
|
$
|
22,193
|
|
The following table presents the reconciliation of weighted
average shares used in computing basic and diluted net income
(loss) per common share:
|
|
Three Months
Ended
|
|
|
Nine Months
Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
|
2023
|
|
|
2022
|
|
Weighted average shares
used to compute basic
net income
(loss) per share
|
|
|
36,142,255
|
|
|
|
35,402,086
|
|
|
|
35,882,826
|
|
|
|
35,265,193
|
|
Plus effect of dilutive
securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based awards from
employee equity plans
|
|
|
—
|
|
|
|
129,718
|
|
|
|
—
|
|
|
|
236,416
|
|
Convertible senior
notes
|
|
|
—
|
|
|
|
1,807,141
|
|
|
|
—
|
|
|
|
—
|
|
Weighted average shares
used to compute
diluted
net income (loss) per share
|
|
|
36,142,255
|
|
|
|
37,338,945
|
|
|
|
35,882,826
|
|
|
|
35,501,609
|
|
The following table presents the net income (loss) per common
share - basic and diluted:
|
|
Three Months
Ended
|
|
|
Nine Months
Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
|
2023
|
|
|
2022
|
|
Net income (loss) per
common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.65)
|
|
|
$
|
2.30
|
|
|
$
|
(2.32)
|
|
|
$
|
0.63
|
|
Diluted
|
|
$
|
(0.65)
|
|
|
$
|
2.22
|
|
|
$
|
(2.32)
|
|
|
$
|
0.63
|
|
Investors and Media:
Rod MacLeod, CFO
Nevro Corp.
ir@nevro.com
Greg Chodaczek
Gilmartin Group LLC
greg@gilmartinir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-reports-third-quarter-2023-financial-results-provides-fourth-quarter-guidance-and-updates-full-year-2023-guidance-301974812.html
SOURCE Nevro Corp.